Dr. David A. Newsome was also highlighted on a medical news segment by New
Orleans CBS news affiliate, WWLTV channel 4, entitled, "Copper, drinking
water and vitamins." This segment can be viewed through Pipex's website,
www.pipexinc.com.

With the assistance of Dr. Joseph A. Quinn, Associate Professor of
Neurology at the Oregon Health & Sciences University (OHSU), 52 frozen
samples taken from Alzheimer's disease patients (n=40) and age-matched
controls (n=12), with an average age of 70 years were analyzed on a blinded
basis for levels of serum free copper using the FreeBound diagnostic
device. A seventy percent (70%) increase in free serum copper was detected
in Alzheimer's disease patients versus age-matched controls (p < 0.02).
Additionally, percent free copper detected was also statistically
significantly higher in AD patients than age matched controls (p < 0.018).
The percent of free serum copper is the amount of free serum copper
expressed as a percent of total serum copper. These samples were provided
by the Oregon Alzheimer's disease center.

The following table presents the results of the study using FreeBound:

David A. Newsome, M.D., Chief Scientific Officer of Pipex, commented,
"These highly statistically significant findings confirm previously
reported scientific results implicating the involvement of elevated levels
of 'free' copper in the pathogenesis of Alzheimer's disease. One
possibility is that these patients present with increased 'free' copper is
due to their dietary source of highly oxidative mineral. It is well known
that many municipal tap water sources as well as dietary supplements, such
as multi-vitamins which generally contain up to 2mg of free copper, can
supply more copper than an elderly patient might need. FreeBound's ability
to detect unbound copper is seminal to creating therapeutic modalities for
the treatment of this devastating CNS disease, as well as being able to
detect other copper mediated disorders, such as Wilson's disease,
Parkinson's disease, Amyotrophic lateral sclerosis (ALS), autism and
schizophrenia."

Steve H. Kanzer, Chairman and Chief Executive Officer of Pipex, commented,
"The purpose of this study is to build upon and confirm free copper's
involvement in Alzheimer's disease. These results, along with our recent
results using COPREXA, our lead anti-copper molecule which reduced
insoluble amyloid-beta, a key AD protein by 40% (p < 0.05) in animal
models, provides additional basis for further testing of this approach in
this important CNS-localized disease. Our FreeBound diagnostic device
should allow clinicians to pre-select patients with elevated levels of CNS
copper who might benefit from copper-reduction therapy."

John Althaus, Vice President of Advanced Technology and co-inventor of
FreeBound commented, "Traditional methods to detect levels of free copper
in serum are indirect, inconvenient and slow and can easily lead to
inaccurate free copper values. These traditional methods may have also led
to misdiagnosis and incorrect pharmacologic treatment of these patients.
As a scientist, I am extremely pleased with the performance and versatile
nature of our FreeBound diagnostic device and look forward to utilizing it
in further clinical tests, to monitor the longitudinal effects of COPREXA
therapy."

Clinical Correlation of Copper and Alzheimer's Disease

Over the last several years, an increasing body of evidence points to
dysfunctional copper homeostasis in the pathogenesis of dementia. Most
recently, a published observational six year study in 3718 patients over
the age of 65, concluded that subjects that consumed a typical amount of a
copper supplement (1.6mg of copper a day) when taken together with a high
saturated and trans fat diet results in an equivalent of 19 years of mental
decline (p < 0.001) (2).

In a separate European clinical study conducted in 53 patients, correlated
the levels of the highly reactive "free copper" (also known as copper not
bound to protein) pool in serum to disease severity in AD patients versus
aged-matched control patients. These results demonstrated that the "free
copper" serum pool was highly increased in AD patients (4).

These clinical studies are complemented by preclinical studies that show
that AD amyloid-betta plaques when treated with copper chelating agents in
vitro loosen and reverse fibril formation as determined by spectroscopy.

Subject to initial and necessary registration clinical trials to support
its use in treating AD, COPREXA's specificity and unique mechanism of
action for lowering toxic free copper levels in the CNS, combined with its
history of success in completed pivotal clinical trials of
neurologically-presenting Wilson's disease, may make it highly useful in
the treatment of both the acute cognitive dysfunction
(copper-mediated synaptic excitotoxicity) as well as long-term
neurodegenerative aspect (copper-induced oxidation and neuronal death) of
AD. COPREXA's ability to specifically bind only toxic free copper, as
opposed to increasing free copper levels by virtue of liberating bound
copper, for example, amongst other properties, we believe differentiates
COPREXA from other non-specific metal chelating compounds previously
investigated for neurodegenerative diseases.

About FreeBound Device

Copper, an essential metal, is made available to organs throughout the body
via the systemic circulation via a tightly regulated system of copper
chaperones and copper transport proteins. Normally, approximately 90% or
more of serum copper is tightly bound to the serum copper chaperone called
ceruloplasmin (Cp). The remaining 10% of serum copper represents the
so-called "free" or "non-ceruloplasmin bound" copper pool and can be highly
toxic to the brain the organ which is most sensitive to the effects of free
copper. In Wilson's disease patients, the free copper pool is expanded and
causes psychiatric symptoms and neurodegeneration in affected patients.

Direct and accurate measurement of this important toxic pool of free copper
in serum has until now remained elusive. The current standard methodology
for measuring free copper relies instead on an inexact indirect estimate
involving a two step process. First, total serum copper is typically
measured using an expensive and time consuming technique called atomic
absorption. Second, serum Cp concentrations are determined by immunoassay
or enzymatic assay. Once Cp is determined, the estimated amount of copper
atoms believed to be bound to Cp is calculated and subtracted from total
copper to arrive at an estimate of free copper in serum. The result is an
inexact, expensive and time consuming process that carries a large
potential for error based on erroneous assumptions and experimental
deviations from multiple measurements.

We believe that by using the FreeBound device, free copper levels can be
determined using technology similar to and as simple to use as a glucometer
that incorporates electrochemical detection. Serum is applied to test
strips attached to a meter. The meter is programmed to separate and
measure free copper versus Cp-bound copper on the test strip immediately
displaying the results on the meter.

About COPREXA

COPREXA is an oral, small-molecule, anti-copper agent that is highly
specific for the reduction of free copper in serum, the most toxic form of
copper in the body, and is thus ideally suited for the treatment of central
nervous system (CNS) diseases in which abnormal serum and CNS copper
homeostasis are implicated. COPREXA has completed pivotal clinical trials
for the treatment of neurologically presenting Wilson's Disease, an orphan
disease of the CNS, and Pipex plans to file an NDA with the FDA for this
indication during this month, November 2007.

Pipex is also developing COPREXA for fibrotic disorders based upon the
rationale that the fibrotic disease process is dependent upon the
availability of free copper in the body. COPREXA has demonstrated the
ability to inhibit fibrosis in a number of well established animal models
through the sequestration of available copper and inhibition of key
fibrotric cytokines, including secreted protein acid rich in cysteine
(SPARC), NFkappaB, TGF-betta, FGF-2, IL-1, IL-6, IL-8, and connective
tissue growth factor (CTGF).

COPREXA has also completed a one year phase I/II clinical trial for the
treatment of refractory Idiopathic Pulmonary Fibrosis (IPF), a deadly lung
disease. Pending regulatory feedback on such a study, Pipex is planning to
launch a phase III registration clinical for the treatment of IPF with
COPREXA.

References and Further Reading About Copper and Alzheimer's Disease

For further reading on the subject of free copper and Alzheimer's disease,
the following cited references may be quickly and easily accessed at
www.pubmed.gov by simply entering the corresponding PubMed ID:

Pipex Pharmaceuticals, Inc. ("Pipex") is a specialty pharmaceutical company
that is developing proprietary, late-stage drug candidates for the
treatment of neurologic and fibrotic diseases Pipex's strategy is to
exclusively in-license proprietary, clinical-stage drug candidates and
complete the further clinical testing, manufacturing and regulatory
requirements sufficient to seek marketing authorizations via the filing of
New Drug Applications (NDAs) with the FDA in the U.S. and Marketing
Application Authorizations (MAAs) with the European Medicines Evaluation
Agency (EMEA).

For further information, please visit, www.pipexinc.com. This press release
contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, that reflect Pipex Pharmaceuticals,
Inc. and subsidiaries ("we" or "our") current expectations about its future
results, performance, prospects and opportunities, including statements
regarding the potential use of FreeBound or its use as a diagnostic tool,
COPREXA™ for the treatment of Alzheimer's disease, inflammatory and
fibrotic diseases, as well as the prospects for regulatory filings in the
treatment of neurologic Wilson's disease, including filing NDA with the FDA
during November 2007 and that such NDA will be accepted for filing by the
FDA and/or that the FDA will agree with our analysis of data supporting the
safety, clinical efficacy, manufacturing, stability and other regulatory
requirements necessary for COPREXA to be approved for use in neurologically
presenting Wilson's disease or that even if approved for initial
indication, that we will be able to conduct and complete necessary initial
and registration clinical trials required to support and receive FDA
approval for a Supplemental New Drug Application to market COPREXA for the
treatment of Alzheimer's disease or other disease indications, such as,
idiopathic pulmonary fibrosis, for example. Where possible, the Company
has tried to identify these forward-looking statements by using words such
as "anticipates," "believes," "intends," or similar expressions. These
statements are subject to a number of risks, uncertainties and other
factors that could cause actual events or results in future periods to
differ materially from what is expressed in, or implied by, these
statements, including risks set forth in our filings with the Securities
and Exchange Commission. We cannot assure you that we will be able to
successfully develop or commercialize products based on our technologies,
including COPREXA™, TRIMESTA™, SOLOVAX™, EFFIRMA™ or Anti-CD4
802-2, particularly in light of the significant uncertainty inherent in
developing, manufacturing and conducting preclinical and clinical trials of
new pharmaceuticals, and obtaining regulatory approvals, that our
technologies will prove to be safe and effective, that our cash
expenditures will not exceed projected levels, that we will be able to
obtain future financing or funds when needed, that product development and
commercialization efforts will not be reduced or discontinued due to
difficulties or delays in clinical trials or due to lack of progress or
positive results from research and development efforts, that we will be
able to successfully obtain any further grants and awards, maintain our
existing grants which are subject to performance, that we will be able to
patent, register or protect our technology from challenge and products from
competition or maintain or expand our license agreements with our current
licensors, or that our business strategy will be successful. All
forward-looking statements made in this press release are made as of the
date hereof, and the Company assumes no obligation to update the
forward-looking statements included in this news release whether as a
result of new information, future events, or otherwise, other than as
required by law.